This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Baxter International Hiding in Plain Sight

"Baxter's products aren't that sexy compared to J&J," says Julie Stralow, of the independent financial research firm Morningstar. "But because Baxter is diversified, if there's a problem with one product , something else comes along to save the day."

Baxter is divided into three areas -- biosciences, medical delivery and kidney-disease care. The biosciences group, which accounted for 42% of the first-quarter's $2.9 billion in sales. includes the world's leading treatment for hemophilia as well as therapies for immune disorders and vaccines. Biosciences grew 13% in the first quarter to $1.2 billion.

Kidney dialysis produced sales of $558 million, up 6% from the year-ago quarter. It accounts for 19% of corporate revenue. Medication delivery sales -- syringes, pumps, intravenous products and anesthesia -- rose 8% to $1.1 billion.

Baxter isn't free from stress. Right now, it is dealing with chronic difficulties with an infusion pump that delivers medications and contaminated supplies of the anticoagulant heparin.

Baxter recalled some vials of injectable heparin in January and initiated a broader recall in February. The heparin was linked to "an unusual increase" in allergic reactions. Baxter receives the drug from its U.S. supplier, Scientific Protein Laboratories. This firm relies on China to provide the raw material, which is derived from pig intestines.

Previously, Baxter had been supplying 50% of U.S. heparin, but the company said May 21 that it "will not sell another vial of heparin until the company has helped to create a system in which the quality and safety of heparin is secured."

2 of 4

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG
ABT $47.18 2.00%
BAX $69.95 0.06%
JNJ $100.84 1.30%
AAPL $127.44 2.20%
FB $84.19 4.20%

Markets

DOW 18,047.18 +12.25 0.07%
S&P 500 2,106.99 +6.59 0.31%
NASDAQ 5,022.8560 +28.2540 0.57%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs